Navigation Links
Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
Date:2/14/2013

JERUSALEM, February 14, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin. The FDA has asked Oramed to perform a sub study in a controlled in-patient setting for up to a one-week period. In order to accommodate the FDA's request, Oramed will submit a new IND with a clinical protocol for the aforementioned sub study.

"We are very pleased to be in close and positive communications with the FDA, as well as having a clear path which meets the FDA's input. This positions us for imminent clearance from the FDA to proceed with our planned clinical studies," commented Nadav Kidron , CEO of Oramed.  

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
2. Oramed Pharmaceuticals Announces Reverse Stock Split
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
5. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
8. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
9. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
10. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
11. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Philadelphia, PA (PRWEB) June 18, 2013 ... fiber-optic Ball Lenses engineered of synthetic Sapphire and Glass ... stock sizes from Swiss Jewel Company , of ... performance by expanding and collimating the light beams without ... extreme optical clarity and natural durability (9 mohs) make ...
(Date:6/18/2013)... , June 18, 2013 ... the release of the HELM biomolecular representation standard ... source MIT licence. HELM (Hierarchical Editing ... wide range of biomolecules (e.g. proteins, nucleotides, antibody ... small-molecule and sequence-based informatics methodologies impractical or unusable. ...
(Date:6/18/2013)... Israel , June 18, 2013 ... Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished ... that the company has been granted a United ... the US and Europe for the ... number 8,410,176 B2 is titled Intermediate Compounds and Processes ...
(Date:6/18/2013)... 2013   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... on discovering breakthrough treatments for human disease, announced ... the company as its vice president of marketing, ... commercial experience to Lexicon, including both pre-launch planning ... areas. Mr. Northcott has held commercial ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3
... HAMBURG, Germany, December 16 Eppendorf ... SP systems for,infringement of European patent EP 1 179 180 ... target compound". The import,ban covers any and all imports of ... authorities are required to confiscate any,violating products. , ...
... Mass., Dec. 15 Repligen Corporation (Nasdaq: RGEN ) ... funding to support the ongoing development of new treatments for ... grant will support the completion of preclinical GLP toxicology testing ... trials. Support from the MDA not only provides important ...
... ... developed and are opening up a new area of research for studies at the ... angle, meniscus height, evaporation rate and viscosity - all in a single force distance ... (PRWEB) ...
Cached Biology Technology:Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 2New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 3
(Date:6/18/2013)... 2013). A team of internationally recognized feline experts including ... from the University of Lincoln, U.K. and Dr Ilona ... invited by the International Society of Feline Medicine (ISFM) ... compile guidelines for veterinarians, owners and those working with ... the domestic cat. The new guidelines appear in the ...
(Date:6/17/2013)... to high levels of air pollution while pregnant were up ... as women who lived in areas with low pollution, according ... (HSPH). It is the first large national study to examine ... "Our findings raise concerns since, depending on the pollutant, 20% ... areas where risk of autism was elevated," said lead author ...
(Date:6/17/2013)... identified a new virus in patients with severe brain ... whether the virus is responsible for the symptoms of ... of 28 out of 644 patients with severe brain ... not in any of the 122 patients with non-infectious ... brain and central nervous system are often fatal and ...
Breaking Biology News(10 mins):Feline behavior experts release guidelines to improve the welfare of cats 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3
... Samuel Waxman Cancer Research Foundation (SWCRF) has awarded 13 ... $1.54 million. The 16 grants represent a portion of ... award more than $2 million this year to cancer ... scientific minds in differentiation therapyreprogramming cancer cellsa hallmark of ...
... July 13 InQ Biosciences, a provider of innovative technologies for ... InQ™ Cell Research System during the fourth quarter of 2010. InQ is ... vivo environment for studying stem cells, plus nerve, brain, and other ... , , ...
... at the UK National Stem Cell Network annual science ... approach to treating heart attack and cardiomyopathy using stem ... Imperial College London, said "Recent clinical trials using stem ... terms of safety but unfortunately the bone marrow stem ...
Cached Biology News:The Samuel Waxman Cancer Research Foundation awards $1.54 million in research grants for 2010-2011 2The Samuel Waxman Cancer Research Foundation awards $1.54 million in research grants for 2010-2011 3InQ Biosciences Introduces First Fully Integrated Cell Research System 2InQ Biosciences Introduces First Fully Integrated Cell Research System 3Improving clinical use of stem cells to repair heart damage 2
... PCR Workstation brings together UV irradiation and ... environment against PCR contamination! Quickly inactivate ... Maintain a clean environment with antimicrobial coated ... reagents within minutes with built-in 30-minute timer ...
... Recombinant Enterokinase (rEK) is a highly purified ... enterokinase, a serine protease which recognizes the ... (AspAspAspAspLys?) and has similar enzymatic activity (1). ... and purified to yield the highest activity ...
... of a Hybridizer and UV Crosslinker (254nm UV) ... , This unique, new design for the ... one location , Hybridizer and Crosslinker portions ... , The Crosslinker is also available as ...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
Biology Products: